Maravai LifeSciences Inc... (MRVI)
NASDAQ: MRVI
· Real-Time Price · USD
2.67
-0.12 (-4.30%)
At close: Sep 12, 2025, 3:59 PM
2.67
0.00%
After-hours: Sep 12, 2025, 04:57 PM EDT
Maravai LifeSciences Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biologics Safety Testing Segment Revenue | 16.31M | 18.1M | 29.42M | 15.25M | 14.92M | 18.16M | 15.32M | 15.64M | 15.65M | 17.57M | 15.42M | 16.38M | 17.48M | 20.64M | 15.93M | 16.63M | 18.21M | 52.95M |
| Biologics Safety Testing Segment Revenue Growth | -9.88% | -38.49% | +92.91% | +2.25% | -17.87% | +18.57% | -2.05% | -0.07% | -10.95% | +13.95% | -5.85% | -6.30% | -15.30% | +29.55% | -4.16% | -8.69% | -65.61% | n/a |
| Nucleic Acid Production Segment Revenue | 31.09M | 28.75M | 100.38M | 49.95M | 58.48M | 46.02M | 58.83M | 51.23M | 53.27M | 61.45M | 189.29M | 174.88M | 225.25M | 223.65M | 212.51M | 182.9M | 192.52M | 372.03M |
| Nucleic Acid Production Segment Revenue Growth | +8.12% | -71.36% | +100.98% | -14.60% | +27.09% | -21.77% | +14.83% | -3.82% | -13.32% | -67.54% | +8.24% | -22.36% | +0.71% | +5.24% | +16.19% | -5.00% | -48.25% | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|
| Asia Pacific Revenue | 8.16M | 10.56M | 45.32M | 22.92M | 23.42M | 21.14M | 72.82M | 24.62M | 15.98M |
| Asia Pacific Revenue Growth | -22.72% | -76.71% | +97.74% | -2.12% | +10.79% | -70.97% | +195.73% | +54.09% | n/a |
| Emea Revenue | 8.39M | 6.88M | 25.23M | 7.46M | 17.55M | 9.37M | 42.3M | 7.62M | 53.72M |
| Emea Revenue Growth | +22.06% | -72.73% | +237.97% | -57.46% | +87.36% | -77.86% | +454.97% | -85.81% | n/a |
| Latin And Central America Revenue | 205K | 146K | 230K | 125K | 120K | 307K | 422K | 105K | 220K |
| Latin And Central America Revenue Growth | +40.41% | -36.52% | +84.00% | +4.17% | -60.91% | -27.25% | +301.90% | -52.27% | n/a |
| North America Revenue | 30.64M | 29.27M | 59.03M | 34.69M | 32.32M | 33.37M | 106.54M | 34.52M | 78.3M |
| North America Revenue Growth | +4.68% | -50.42% | +70.15% | +7.35% | -3.16% | -68.68% | +208.68% | -55.92% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 38.58M | 39.56M | 41.24M | 39.09M | 40.56M | 31.2M | 33.63M | 38.86M | 35.38M | 38.67M | 37.2M | 30.8M | 28.06M | 33.2M | 25.58M | 25.19M | 24.09M | 23.24M | 41.62M | 20.51M | 15.99M | 16.13M | 15.78M |
| Selling, General, and Administrative Revenue Growth | -2.50% | -4.07% | +5.52% | -3.62% | +30.00% | -7.22% | -13.48% | +9.86% | -8.52% | +3.95% | +20.81% | +9.74% | -15.48% | +29.78% | +1.56% | +4.58% | +3.65% | -44.17% | +102.93% | +28.28% | -0.86% | +2.17% | n/a |
| Research and Development Revenue | 4.88M | 4.89M | 4.56M | 4.34M | 5.28M | 5.03M | 4.59M | 4.35M | 4.19M | 4.14M | 5.01M | 5.39M | 4.27M | 3.69M | 9.18M | 1.95M | 1.93M | 2.16M | 2.09M | 1.87M | 1.6M | 3.74M | 979K |
| Research and Development Revenue Growth | -0.12% | +7.17% | +5.00% | -17.79% | +5.01% | +9.53% | +5.68% | +3.65% | +1.18% | -17.28% | -7.01% | +26.09% | +15.67% | -59.77% | +370.97% | +0.93% | -10.72% | +3.44% | +11.99% | +16.75% | -57.26% | +282.43% | n/a |